Evidence Level
Echinacea research has produced inconsistent findings due to variations in species, plant parts, and preparation methods. A meta-analysis by Shah et al. (2007) of 14 randomized controlled trials (RCTs) found significant benefits for reducing cold incidence and duration, particularly with Echinacea purpurea aerial parts. However, a later Cochrane review by Karsch-Volk et al. (2014) reported modest effects that did not consistently reach statistical significance. Recent studies provide additional insights: Pham et al. (2025) conducted a systematic review and meta-analysis of 9 RCTs involving 3,169 participants, concluding that Echinacea purpurea significantly reduced upper respiratory tract infection (URTI) duration, incidence, and antibiotic use in children, though adverse events were moderately increased. In contrast, David and Cunningham (2019) found a 22% reduction in URTI risk but no significant effect on duration or safety across 16 studies with 4,725 participants. Deccy et al. (2024) reported no impact of Echinacea supplementation on aerobic capacity or erythropoiesis in athletes based on a meta-analysis of 107 individuals. The immunological mechanisms involve alkamides and polysaccharides activating macrophages via CB2 and TLR receptors, as previously characterized (Schoop et al., 2006).